0001654954-21-012056.txt : 20211112
0001654954-21-012056.hdr.sgml : 20211112
20211112120130
ACCESSION NUMBER: 0001654954-21-012056
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210113
FILED AS OF DATE: 20211112
DATE AS OF CHANGE: 20211112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Breen Michael Martin
CENTRAL INDEX KEY: 0001863633
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40023
FILM NUMBER: 211401769
MAIL ADDRESS:
STREET 1: LOWSLEY HOUSE 133 HEADLEY ROAD
CITY: LIPHOOK
STATE: X0
ZIP: GU30 7PU
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GT Biopharma, Inc.
CENTRAL INDEX KEY: 0000109657
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 941620407
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9350 WILSHIRE BLVD.
STREET 2: SUITE 203
CITY: BEVERLY HILLS
STATE: CA
ZIP: 90212
BUSINESS PHONE: (800) 304-9888
MAIL ADDRESS:
STREET 1: 9350 WILSHIRE BLVD.
STREET 2: SUITE 203
CITY: BEVERLY HILLS
STATE: CA
ZIP: 90212
FORMER COMPANY:
FORMER CONFORMED NAME: OXIS INTERNATIONAL INC
DATE OF NAME CHANGE: 19940916
FORMER COMPANY:
FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/
DATE OF NAME CHANGE: 19850312
3
1
section16.xml
PRIMARY DOCUMENT
X0206
3
2021-01-13
0
0000109657
GT Biopharma, Inc.
GTBP
0001863633
Breen Michael Martin
C/O GT BIOPHARMA, INC.
9350 WILSHIRE BLVD., STE. 203
BEVERLY HILLS
CA
90212
true
false
false
false
10% Senior Convertible Debenture
3.40
2018-09-07
Common Stock
D
10% Senior Convertible Debenture
3.40
2020-06-23
2021-06-23
Common Stock
D
Reflects a 10% Senior Convertible Debenture in the face amount of $100,000. While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of $3.40 (which reflects the applicable conversion price on a post-reverse split basis).
Reflects a 10% Senior Convertible Debenture in the face amount of $30,000. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of $3.40 (which reflects the applicable conversion price on a post-reverse split basis)
/s/ Michael Martin Bree
2021-11-09